Tags: High Cholesterol | bad cholesterol | LDL cholesterol | evolocumab | PCSK9

New Once-Monthly Drug Cuts Cholesterol

Monday, 17 Mar 2014 12:37 PM


Amgen Inc said on Monday its experimental new type of cholesterol fighter met the primary goal of a late-stage trial by significantly cutting "bad" LDL cholesterol among patients with a genetic tendency towards very high levels of the artery clogging fat.
 
Amgen said patients given its injectable drug evolocumab once a month on top of standard daily statin treatments showed "clinically meaningful" improvement compared to statins alone after 12 weeks of treatment.
 
Evolocumab works by blocking PCSK9, a naturally occurring protein that keeps LDL levels elevated in the bloodstream. Other drugmakers, including Pfizer Inc and a partnership between Regeneron Inc and Sanofi, are racing with Amgen to complete trials of potentially lucrative anti-PCSK9 antibodies.
 
ALERT: 4 Things You'll Feel Before a Heart Attack


© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved